Sleep Aids & Wakefulness

These medicines do opposite things. The comparison below is about which problem each family addresses, not about which is better — they are not substitutes and should never be used to counteract one another. Labelled strength is a prescriber's decision and is deliberately not compared.

Swipe the table sideways to see every column.

Use profiles describe the general shape of treatment, not a schedule or an amount. Never use a sedating medicine and a wakefulness agent to offset one another — that pattern is a warning sign, not a strategy, and it warrants a conversation with a doctor.

1. 1Work out which problem you actually have

   Trouble sleeping at night and trouble staying awake in the day are different conditions with different treatments. If you have both, that combination itself is informative — it often points to sleep apnoea, shift work or a mood disorder — and it needs assessing rather than medicating from both ends.

2. 2Look for the cause before the tablet

   Insomnia is often secondary to anxiety, low mood, pain, alcohol, caffeine, screens or an untreated breathing disorder. Daytime sleepiness is very often untreated sleep apnoea, which is common in Australia and frequently undiagnosed. A sleep study or a proper review may be more use than a prescription.

3. 3Ask about the non-drug options first

   For ongoing insomnia, Australian guidance puts cognitive behavioural therapy for insomnia ahead of sleeping tablets. For apnoea-related sleepiness, treating the apnoea comes first. Neither is a consolation prize — they are the recommended starting point, and a good prescriber will raise them.

4. 4Plan the endpoint at the start

   If a short course of a sleeping tablet is agreed, agree at the same time how long it runs, what happens afterwards, and how it will be reduced. Zopiclone is a short-term medicine, and the plan for stopping is part of the prescription, not an afterthought.

Choose by the problem, never by preference. Zopiclone addresses difficulty sleeping at night and is intended for short-term use only. Modafinil and armodafinil address excessive daytime sleepiness in specific diagnosed conditions. They are not interchangeable, they should never be used to counteract each other, and neither replaces treating the underlying cause. Within each family the differences are brand and labelled strength, and labelled strength is your prescriber's decision.

• Short-term insomnia — difficulty falling asleep, staying asleep or early waking — with zopiclone, for a limited period only
• Insomnia that has not responded to sleep habits and a structured non-drug approach, where a prescriber has decided a short course is warranted
• Excessive daytime sleepiness in narcolepsy — modafinil or armodafinil
• Excessive daytime sleepiness in shift-work sleep disorder
• Residual daytime sleepiness in obstructive sleep apnoea, alongside treatment of the apnoea itself such as CPAP
• Not a treatment for ordinary tiredness, jet lag self-management, study performance or general productivity — none of these is an approved use

• Zopiclone is for short-term use only. Tolerance can develop with continued use, and dependence and withdrawal effects are recognised. It is prescribed for limited periods and reduced gradually rather than stopped abruptly after a sustained course.
• Next-day impairment after zopiclone is common. Do not drive, ride or operate machinery until you are certain you are unaffected — this includes the morning after. Australian road rules place the responsibility on the driver.
• Do not combine zopiclone with alcohol, opioids, benzodiazepines or other sedatives. The combined effect on breathing and consciousness is the serious risk, and it is the mechanism behind the most severe harms associated with sleeping tablets.
• Complex sleep behaviours — sleepwalking, sleep-driving, eating or making calls with no memory of it — have been reported with Z-drugs, sometimes on first use. If anything like this happens, stop and contact your prescriber straight away.
• Modafinil and armodafinil reduce the reliability of hormonal contraception, including the pill, patch, ring, implant and hormonal IUD. An additional or alternative method is needed during treatment and for a period afterwards — your prescriber or pharmacist will tell you how long.
• Seek urgent medical care for a severe or spreading rash, blistering or peeling skin, mouth ulcers with fever, or swelling of the face, lips or tongue while taking modafinil or armodafinil. Serious skin reactions are rare but recognised. In an emergency in Australia, call 000.
• Tell your prescriber about heart problems, high blood pressure, an irregular heartbeat, a history of psychosis, mania, depression or anxiety, or any history of substance misuse before a wakefulness agent is considered. New or worsening mood or psychiatric symptoms need prompt review.
• Modafinil and armodafinil have recognised risks in pregnancy and are not appropriate for use while pregnant or planning a pregnancy without a specific discussion with your prescriber.
• Using a wakefulness agent to manage untreated sleep apnoea leaves the apnoea — and its cardiovascular consequences — untreated. These medicines are used alongside treatment of the apnoea, not instead of it.
• Neither family is approved for study performance, work productivity, staying awake to drive, or managing ordinary tiredness. Using them that way means taking on the risks of a prescription medicine without the assessment that makes it reasonable.
• Both are prescription-controlled in Australia, and Australian jurisdictions operate real-time prescription monitoring for medicines of concern. Take only what has been prescribed for you, never share it, and do not obtain it from multiple sources.
• Always read the patient information leaflet supplied with the product, and check the packaging, batch number and expiry before use.

• Confirm the prescription position

  Zopiclone, modafinil and armodafinil are all Prescription Only Medicines in Australia and are subject to prescribing controls because of dependence and misuse potential. A source that presents itself as a way around an assessment is telling you something about how it operates.

• Verify the molecule, not the brand

  Zopisign is zopiclone; modafinil and armodafinil are sold under many names internationally. Check the active ingredient and labelled strength printed on the pack against your prescription. Brand names change across markets; the active ingredient does not.

• Understand ARTG status

  The Australian Register of Therapeutic Goods lists products the TGA has assessed for supply here. Generics made for other markets may be produced to Good Manufacturing Practice standards without ARTG registration. Know which you are ordering, and mention it to your pharmacist.

• Inspect the packaging carefully

  Intact manufacturer packaging, unbroken blister foil, a legible batch number and expiry, uniform tablets, and an included patient information leaflet. Sedatives and stimulant-like medicines are heavily counterfeited, so anything loose, unlabelled, misspelt or short-dated should not be used.

• Assess the seller

  A verifiable business address, a working contact route, Australian dollar pricing, a stated dispatch and delivery window, a published returns and complaints process, and a clear privacy policy. Medicines with dependence potential are the wrong category in which to accept an anonymous supplier.

• Order to a course, not a stockpile

  Holding large quantities of a sedative at home is a risk in itself — for tolerance, for accidental access by others, and for expiry. Order what the prescribed course requires and return anything unused to a pharmacy for disposal.

• Orders are dispatched within one business day of payment clearing, with confirmation by email and tracking where available.
• Standard delivery is 2–4 business days Australia-wide, free on orders over $150. Regional and remote destinations can take longer.
• Plain, unbranded outer packaging on every parcel — nothing outside identifies the contents.
• No cold-chain handling is required for anything in this range. Store tablets below 25°C in the original blister, away from heat, direct sunlight and humidity.
• Store sedating medicines securely and out of sight — not on a bedside table where a half-asleep person, a child or a visitor can reach them.
• Keep tablets in the pack they arrived in so the active ingredient, batch and expiry stay readable, and do not mix a sedating tablet into a shared pill organiser.
• Return unused or expired tablets to a pharmacy for safe disposal rather than putting them in household waste.

Z-drug

The informal name for a group of sleeping medicines, including zopiclone, that act on the same receptor system as benzodiazepines. Used for short-term insomnia because of tolerance and dependence potential.

Insomnia

Persistent difficulty falling asleep, staying asleep or waking too early, with daytime consequences, despite adequate opportunity to sleep. It is a diagnosis, not simply a bad night.

CBT-i

Cognitive behavioural therapy for insomnia — a structured, non-drug programme addressing the thoughts and habits that keep insomnia going. Australian guidance treats it as the first-line approach for ongoing insomnia.

Sleep hygiene

The practical habits that support sleep: consistent times, a dark and cool room, limiting caffeine and alcohol, and keeping screens and work out of bed. Useful, but on its own rarely enough for established insomnia.

Obstructive sleep apnoea

Repeated partial or complete blockage of the upper airway during sleep, causing fragmented sleep and daytime sleepiness. Common in Australia and frequently undiagnosed; treating it is the answer to the sleepiness it causes.

Narcolepsy

A neurological condition causing overwhelming daytime sleepiness and sudden sleep episodes, sometimes with sudden loss of muscle tone. Diagnosed by a sleep specialist, usually after a sleep study.

Shift-work sleep disorder

Insomnia or excessive sleepiness arising because a work roster conflicts with the body clock. Managing light exposure, roster design and sleep opportunity matters as much as any medicine.

Next-day impairment

Residual drowsiness, slowed reactions or reduced concentration the morning after a sedating sleep medicine. It is common with Z-drugs and is the main reason driving is a specific concern.

Real-time prescription monitoring

Australian systems that let prescribers and pharmacists see recent supply of medicines of concern at the point of care, reducing duplicate supply and harm.

Or read the reference page for an individual active ingredient:

For independent, Australian information about the medicines in this range, we point customers to the following bodies. Search for the medicine by name on their sites rather than relying on overseas material.

• Therapeutic Goods Administration (TGA)
• Australian Register of Therapeutic Goods (ARTG)
• Healthdirect Australia
• Australian Commission on Safety and Quality in Health Care
• Pharmaceutical Benefits Scheme (PBS)